Document


(Unaudited; Dollars in Millions)	THIRD QUARTER
			Percent Change
Sales to customers by geographic area	2026	2025	Total		Operations	Currency
U.S.	$14,959	13,708	9.1	%	9.1	—
Europe	5,405	5,440	(0.6)		1.0	(1.6)
Western Hemisphere excluding U.S.	1,385	1,231	12.5		8.0	4.5
Asia-Pacific, Africa	3,650	3,614	1.0		1.0	0.0
International	10,440	10,285	1.5		1.8	(0.3)
Worldwide	$25,399	23,993	5.9	%	6.0	(0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


(Unaudited; Dollars in Millions)	NINE MONTHS
			Percent Change
Sales to customers by geographic area	2026	2025	Total		Operations	Currency
U.S.	$42,822	39,557	8.3	%	8.3	—
Europe	16,979	15,937	6.5		2.3	4.2
Western Hemisphere excluding U.S.	3,987	3,604	10.6		4.5	6.1
Asia-Pacific, Africa	10,983	10,531	4.3		3.6	0.7
International	31,949	30,072	6.2		3.0	3.2
Worldwide	$74,771	69,629	7.4	%	6.0	1.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


(Unaudited; Dollars in Millions)	THIRD QUARTER
					Percent Change
Sales to customers by segment of business		2026		2025	Total		Operations	Currency
Innovative Medicine
U.S.		$	10,447	9,402	11.1	%	11.1	—
International		6,310		6,161	2.4		3.0	(0.6)
		16,757		15,563	7.7		7.9	(0.2)
MedTech
U.S.		4,512		4,306	4.8		4.8	—
International		4,130		4,124	0.1		0.1	0.0
		8,642		8,430	2.5		2.5	0.0
U.S.		14,959		13,708	9.1		9.1	—
International		10,440		10,285	1.5		1.8	(0.3)
Worldwide		$	25,399	23,993	5.9	%	6.0	(0.1)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


(Unaudited; Dollars in Millions)	NINE MONTHS
					Percent Change
Sales to customers by segment of business		2026		2025	Total		Operations	Currency
Innovative Medicine
U.S.		$	29,297	26,655	9.9	%	9.9	—
International		19,270		17,983	7.2		3.6	3.6
		48,567		44,638	8.8		7.4	1.4
MedTech
U.S.		13,525		12,902	4.8		4.8	—
International		12,679		12,089	4.9		2.2	2.7
		26,204		24,991	4.9		3.5	1.4
U.S.		42,822		39,557	8.3		8.3	—
International		31,949		30,072	6.2		3.0	3.2
Worldwide		$	74,771	69,629	7.4	%	6.0	1.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.


(Unaudited; in Millions Except Per Share Figures)	THIRD QUARTER
	2026				2025				Percent Increase (Decrease)
	Amount			Percent to Sales	Amount			Percent to Sales
Sales to customers	$	25,399		100.0	$	23,993		100.0	5.9
Cost of products sold	8,097			31.9	7,303			30.4	10.9
Gross Profit	17,302			68.1	16,690			69.6	3.7
Selling, marketing and administrative expenses	6,285			24.7	5,922			24.7	6.1
Research and development expense	4,652			18.3	3,672			15.3	26.7
In-process research and development impairments	339			1.4	—			—
Interest (income) expense, net	31			0.1	18			0.1
Other (income) expense, net	5,780			22.8	(478)			(2.0)
Restructuring	181			0.7	63			0.3
Earnings before provision for taxes on income	34			0.1	7,493			31.2	(99.5)
(Benefit from)/Provision for taxes on income	(176)			(0.7)	2,341			9.7	(107.5)
Net earnings	$	210		0.8	$	5,152		21.5	(95.9)

Net earnings per share (Diluted)	$	0.09			$	2.12			(95.8)

Average shares outstanding (Diluted)	2,448.6				2,428.6

Effective tax rate	(517.6)		%		31.2		%

Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income	$	7,672		30.2	$	8,436		35.2	(9.1)
Net earnings	$	6,339		25.0	$	6,801		28.3	(6.8)
Net earnings per share (Diluted)	$	2.59			$	2.80			(7.5)
Effective tax rate	17.4		%		19.4		%

(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.


(Unaudited; in Millions Except Per Share Figures)	NINE MONTHS
	2026				2025				Percent Increase (Decrease)
	Amount			Percent to Sales	Amount			Percent to Sales
Sales to customers	$	74,771		100.0	$	69,629		100.0	7.4
Cost of products sold	24,254			32.4	22,288			32.0	8.8
Gross Profit	50,517			67.6	47,341			68.0	6.7
Selling, marketing and administrative expenses	18,751			25.1	16,923			24.3	10.8
Research and development expense	11,832			15.8	10,413			15.0	13.6
In-process research and development impairments	375			0.5	—			—
Interest (income) expense, net	136			0.2	(62)			(0.1)
Other (income) expense, net	6,405			8.6	(7,692)			(11.1)
Restructuring	247			0.3	144			0.2
Earnings before provision for taxes on income	12,771			17.1	27,615			39.7	(53.8)
Provision for taxes on income	1,792			2.4	5,927			8.6	(69.8)
Net earnings	$	10,979		14.7	$	21,688		31.1	(49.4)

Net earnings per share (Diluted)	$	4.49			$	8.94			(49.8)

Average shares outstanding (Diluted)	2,445.8				2,424.8

Effective tax rate	14.0		%		21.5		%

Adjusted earnings before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income	$	24,153		32.3	$	24,635		35.4	(2.0)
Net earnings	$	20,034		26.8	$	20,206		29.0	(0.9)
Net earnings per share (Diluted)	$	8.19			$	8.33			(1.7)
Effective tax rate	17.1		%		18.0		%


	THIRD QUARTER			NINE MONTHS
(Dollars in Millions Except Per Share Data)	2026		2025	2026		2025
Net Earnings, after tax- as reported		$210	$5,152		$10,979	$21,688

Pre-tax Adjustments
Litigation related		5,519	15		6,116	(6,894)
Intangible Asset Amortization expense		1,240	1,048		3,732	3,435
Restructuring related 1		195	168		533	302
Orthopaedics separation related		369	—		746	—
Acquisition, integration and divestiture related		(34)	97		142	475
(Gains)/losses on securities		10	(387)		(262)	(327)
IPR&D impairments		339	—		375	—
Other		—	2		—	29

Tax Adjustments
Tax impact on special item adjustments 2		(1,677)	(168)		(2,469)	826
Tax legislation and other tax related		168	874		142	672
Adjusted Net Earnings, after tax		$6,339	$6,801		$20,034	$20,206
Average shares outstanding (Diluted)		2,448.6	2,428.6		2,445.8	2,424.8
Adjusted net earnings per share (Diluted)		$2.59	$2.80		$8.19	$8.33
Operational adjusted net earnings per share (Diluted)		$2.61			$8.04

1In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs.

In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.

In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.


Segments
	Innovative Medicine		MedTech		Total
WW As Reported	7.7	%	2.5	%	5.9	%
U.S.	11.1	%	4.8	%	9.1	%
International	2.4	%	0.1	%	1.5	%

WW Currency	(0.2)		0.0		(0.1)
U.S.	—		—		—
International	(0.6)		0.0		(0.3)

WW Operational	7.9	%	2.5	%	6.0	%
U.S.	11.1	%	4.8	%	9.1	%
International	3.0	%	0.1	%	1.8	%

All Other Acquisitions and Divestitures (A&D)	0.1		0.0		0.1
U.S.	0.0		0.0		0.0
International	0.2		0.0		0.1

WW Adjusted Operational Ex A&D	8.0	%	2.5	%	6.1	%
U.S.	11.1	%	4.8	%	9.1	%
International	3.2	%	0.1	%	1.9	%

(A) NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.


Segments
	Innovative Medicine		MedTech		Total
WW As Reported	8.8	%	4.9	%	7.4	%
U.S.	9.9	%	4.8	%	8.3	%
International	7.2	%	4.9	%	6.2	%

WW Currency	1.4		1.4		1.4
U.S.	—		—		—
International	3.6		2.7		3.2

WW Operational	7.4	%	3.5	%	6.0	%
U.S.	9.9	%	4.8	%	8.3	%
International	3.6	%	2.2	%	3.0	%

Caplyta	(0.6)				(0.4)
U.S.	(1.0)				(0.7)
International	0.0				0.0

All Other Acquisitions and Divestitures (A&D)	0.1		0.1		0.1
U.S.	0.0		0.1		0.0
International	0.2		0.0		0.1

WW Adjusted Operational Ex A&D	6.9	%	3.6	%	5.7	%
U.S.	8.9	%	4.9	%	7.6	%
International	3.8	%	2.2	%	3.1	%


	THIRD QUARTER
				% Change
	2026		2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)
ONCOLOGY
US	$	4,267	3,468	23.0	%	23.0	%	—	%
Intl	3,335		3,060	9.0		9.5		(0.5)
WW	7,602		6,529	16.4		16.7		(0.3)

DARZALEX
US	2,528		2,088	21.1		21.1		—
Intl	1,711		1,584	8.0		8.5		(0.5)
WW	4,239		3,672	15.4		15.6		(0.2)

CARVYKTI
US	472		396	19.4		19.4		—
Intl	238		128	85.3		84.1		1.2
WW	710		524	35.5		35.2		0.3

TECVAYLI
US	236		115	*		*		—
Intl	77		62	24.0		25.9		(1.9)
WW	312		177	76.6		77.3		(0.7)

TALVEY
US	112		85	31.6		31.6		—
Intl	59		37	62.9		66.9		(4.0)
WW	171		122	40.9		42.1		(1.2)

RYBREVANT / LAZCLUZE
US	201		136	47.9		47.9		—
Intl	119		61	94.5		98.3		(3.8)
WW	320		198	62.3		63.5		(1.2)

ERLEADA
US	423		378	11.8		11.8		—
Intl	600		558	7.7		7.7		0.0
WW	1,023		936	9.4		9.4		0.0

IMBRUVICA
US	145		211	(31.6)		(31.6)		—
Intl	420		483	(13.2)		(12.6)		(0.6)
WW	563		695	(18.8)		(18.4)		(0.4)

OTHER ONCOLOGY(3)
US	149		61	*		*		—
Intl	111		147	(24.4)		(23.9)		(0.5)
WW	262		207	26.3		26.7		(0.4)

See footnotes at end of schedule

(Dollars in Millions)


	THIRD QUARTER
				% Change
	2026		2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
IMMUNOLOGY
US	$	2,804	2,676	4.8	%	4.8	%	—	%
Intl	1,417		1,493	(5.1)		(4.8)		(0.3)
WW	4,221		4,168	1.3		1.4		(0.1)

TREMFYA
US	1,772		989	79.1		79.1		—
Intl	624		434	43.7		43.4		0.3
WW	2,396		1,424	68.3		68.2		0.1

SIMPONI / SIMPONI ARIA
US	269		309	(13.2)		(13.2)		—
Intl	299		377	(20.6)		(20.3)		(0.3)
WW	568		687	(17.3)		(17.1)		(0.2)

REMICADE
US	258		326	(20.8)		(20.8)		—
US Exports(4)	12		19	(37.1)		(37.1)		—
Intl	124		132	(6.2)		(7.5)		1.3
WW	394		476	(17.3)		(17.6)		0.3

STELARA
US	368		1,022	(64.0)		(64.0)		—
Intl	349		549	(36.5)		(35.5)		(1.0)
WW	716		1,570	(54.4)		(54.0)		(0.4)

OTHER IMMUNOLOGY
US	126		12	*		*		—
Intl	21		0	*		*		*
WW	147		12	*		*		*

NEUROSCIENCE
US	1,733		1,367	26.8		26.8		—
Intl	642		658	(2.4)		(1.7)		(0.7)
WW	2,375		2,024	17.3		17.6		(0.3)

SPRAVATO
US	559		405	37.9		37.9		—
Intl	66		53	22.7		21.4		1.3
WW	624		459	36.1		36.0		0.1

CAPLYTA
US	398		240	66.1		66.1		—
Intl	—		—	—		—		—
WW	398		240	66.1		66.1		—

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US	739		664	11.4		11.4		—
Intl	258		267	(3.0)		(2.4)		(0.6)
WW	998		929	7.3		7.5		(0.2)

See footnotes at end of schedule


	THIRD QUARTER
				% Change
	2026		2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CONCERTA / methylphenidate
US	$	6	14	(56.3)	%	(56.3)	%	—	%
Intl	138		127	8.1		8.9		(0.8)
WW	143		140	2.1		2.9		(0.8)
OTHER NEUROSCIENCE
US	32		46	(30.6)		(30.6)		—
Intl	180		210	(14.3)		(13.1)		(1.2)
WW	212		256	(17.3)		(16.2)		(1.1)
PULMONARY HYPERTENSION (PH)
US	588		815	(27.8)		(27.8)		—
Intl	309		300	2.9		4.1		(1.2)
WW	897		1,115	(19.5)		(19.2)		(0.3)

UPTRAVI
US	383		392	(2.2)		(2.2)		—
Intl	100		92	8.9		8.4		0.5
WW	483		484	(0.1)		(0.2)		0.1

OPSUMIT / OPSYNVI
US	193		409	(52.8)		(52.8)		—
Intl	179		168	5.9		7.8		(1.9)
WW	372		578	(35.7)		(35.2)		(0.5)

OTHER PULMONARY HYPERTENSION
US	12		13	(7.3)		(7.3)		—
Intl	30		39	(23.8)		(21.2)		(2.6)
WW	42		53	(19.7)		(17.7)		(2.0)

INFECTIOUS DISEASES (ID)
US	317		326	(2.7)		(2.7)		—
Intl	496		501	(1.2)		(0.1)		(1.1)
WW	813		829	(1.8)		(1.1)		(0.7)

EDURANT / rilpivirine
US	5		7	(31.6)		(31.6)		—
Intl	382		378	1.0		2.4		(1.4)
WW	386		385	0.4		1.8		(1.4)

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US	307		315	(2.5)		(2.5)		—
Intl	74		81	(8.9)		(7.7)		(1.2)
WW	381		397	(3.8)		(3.6)		(0.2)

OTHER INFECTIOUS DISEASES
US	5		4	29.9		29.9		—
Intl	40		42	(6.2)		(7.9)		1.7
WW	46		47	(3.0)		(4.5)		1.5

See footnotes at end of schedule


	THIRD QUARTER
				% Change
	2026		2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US	$	736	750	(1.9)	%	(1.9)	%	—	%
Intl	112		149	(24.3)		(23.8)		(0.5)
WW	849		899	(5.6)		(5.5)		(0.1)

XARELTO
US	653		635	2.7		2.7		—
Intl	—		—	—		—		—
WW	653		635	2.7		2.7		—

OTHER
US	84		115	(27.2)		(27.2)		—
Intl	112		149	(24.3)		(23.8)		(0.5)
WW	197		264	(25.5)		(25.3)		(0.2)

TOTAL PH, ID, CVM
US	1,643		1,891	(13.2)		(13.2)		—
Intl	917		950	(3.5)		(2.5)		(1.0)
WW	2,560		2,843	(9.9)		(9.6)		(0.3)

TOTAL INNOVATIVE MEDICINE
US	10,447		9,402	11.1		11.1		—
Intl	6,310		6,161	2.4		3.0		(0.6)
WW	$16,757		15,563	7.7	%	7.9	%	(0.2)	%


	THIRD QUARTER
				% Change
	2026		2025	Reported		Operational(1)		Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR
US	$	1,397	1,306	7.0	%	7.0	%	—	%
Intl	910		908	0.2		(0.2)		0.4
WW	2,307		2,213	4.3		4.1		0.2

ELECTROPHYSIOLOGY
US	771		720	7.0		7.0		—
Intl	717		698	2.8		1.8		1.0
WW	1,487		1,418	4.9		4.4		0.5

ABIOMED
US	335		336	(0.3)		(0.3)		—
Intl	78		86	(10.4)		(6.5)		(3.9)
WW	412		423	(2.3)		(1.5)		(0.8)

SHOCKWAVE
US	261		220	18.8		18.8		—
Intl	64		59	9.3		11.2		(1.9)
WW	325		278	16.8		17.2		(0.4)

OTHER CARDIOVASCULAR
US	31		30	3.6		3.6		—
Intl	50		65	(21.9)		(23.1)		1.2
WW	81		95	(13.9)		(14.7)		0.8

SURGERY
US	1,070		1,031	3.7		3.7		—
Intl	1,459		1,511	(3.4)		(4.2)		0.8
WW	2,528		2,542	(0.6)		(1.0)		0.4

ADVANCED
US	500		477	5.1		5.1		—
Intl	654		688	(5.0)		(5.7)		0.7
WW	1,155		1,165	(0.9)		(1.3)		0.4

GENERAL
US	568		555	2.4		2.4		—
Intl	805		823	(2.2)		(3.0)		0.8
WW	1,373		1,378	(0.3)		(0.8)		0.5


	THIRD QUARTER
			% Change
	2026	2025	Reported		Operational(1)		Currency
MEDTECH SEGMENT(2)(Continued)
VISION
US	$596	571	4.3	%	4.3	%	—	%
Intl	865	828	4.4		5.6		(1.2)
WW	1,461	1,400	4.4		5.1		(0.7)

CONTACT LENSES / OTHER
US	465	456	1.9		1.9		—
Intl	588	562	4.7		6.2		(1.5)
WW	1,053	1,018	3.5		4.3		(0.8)

SURGICAL
US	132	116	13.6		13.6		—
Intl	276	266	3.8		4.3		(0.5)
WW	408	383	6.8		7.1		(0.3)

ORTHOPAEDICS
US	1,448	1,396	3.8		3.8		—
Intl	898	878	2.2		2.9		(0.7)
WW	2,345	2,274	3.2		3.4		(0.2)

HIPS
US	271	262	3.5		3.5		—
Intl	148	144	2.6		3.0		(0.4)
WW	419	405	3.1		3.3		(0.2)

KNEES
US	221	216	2.1		2.1		—
Intl	165	160	3.0		4.4		(1.4)
WW	386	377	2.5		3.1		(0.6)

TRAUMA
US	555	512	8.6		8.6		—
Intl	288	281	2.4		2.8		(0.4)
WW	844	793	6.4		6.5		(0.1)

SPINE, SPORTS & OTHER
US	401	406	(1.2)		(1.2)		—
Intl	296	293	1.3		2.0		(0.7)
WW	697	698	(0.1)		0.1		(0.2)

TOTAL MEDTECH
US	4,512	4,306	4.8		4.8		—
Intl	4,130	4,124	0.1		0.1		0.0
WW	$8,642	8,430	2.5	%	2.5	%	0.0	%


	NINE MONTHS
			% Change
	2026	2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)
ONCOLOGY
US	$11,951	9,866	21.1	%	21.1	%	—	%
Intl	10,030	8,652	15.9		11.9		4.0
WW	21,981	18,519	18.7		16.8		1.9

DARZALEX
US	7,171	5,934	20.9		20.9		—
Intl	5,239	4,514	16.1		11.9		4.2
WW	12,410	10,448	18.8		17.0		1.8

CARVYKTI
US	1,377	1,072	28.5		28.5		—
Intl	587	260	*		*		*
WW	1,964	1,332	47.4		45.5		1.9

TECVAYLI
US	549	334	64.4		64.4		—
Intl	225	160	40.6		37.7		2.9
WW	774	494	56.7		55.7		1.0

TALVEY
US	325	235	38.1		38.1		—
Intl	172	79	*		*		*
WW	497	314	58.3		57.5		0.8

RYBREVANT / LAZCLUZE
US	566	388	46.1		46.1		—
Intl	300	130	*		*		*
WW	866	518	67.4		67.5		(0.1)

ERLEADA
US	1,161	1,048	10.8		10.8		—
Intl	1,806	1,567	15.3		10.8		4.5
WW	2,967	2,615	13.5		10.8		2.7

IMBRUVICA
US	437	685	(36.3)		(36.3)		—
Intl	1,386	1,453	(4.7)		(8.7)		4.0
WW	1,822	2,139	(14.8)		(17.5)		2.7

OTHER ONCOLOGY(3)
US	365	171	*		*		—
Intl	314	488	(35.7)		(36.0)		0.3
WW	680	659	3.2		2.9		0.3

See footnotes at end of schedule

(Dollars in Millions)


	NINE MONTHS
			% Change
	2026	2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
IMMUNOLOGY
US	$7,031	7,377	(4.7)	%	(4.7)	%	—	%
Intl	4,414	4,492	(1.7)		(4.9)		3.2
WW	11,445	11,868	(3.6)		(4.8)		1.2

TREMFYA
US	4,279	2,384	79.5		79.5		—
Intl	1,771	1,181	49.9		44.7		5.2
WW	6,050	3,566	69.7		67.9		1.8

SIMPONI / SIMPONI ARIA
US	798	906	(11.9)		(11.9)		—
Intl	1,035	1,130	(8.4)		(11.4)		3.0
WW	1,833	2,036	(10.0)		(11.6)		1.6

REMICADE
US	742	923	(19.6)		(19.6)		—
US Exports(4)	40	63	(36.6)		(36.6)		—
Intl	372	413	(9.8)		(12.9)		3.1
WW	1,154	1,398	(17.5)		(18.4)		0.9

STELARA
US	924	3,081	(70.0)		(70.0)		—
Intl	1,188	1,768	(32.8)		(34.9)		2.1
WW	2,112	4,848	(56.4)		(57.2)		0.8

OTHER IMMUNOLOGY
US	249	21	*		*		—
Intl	48	0	*		*		*
WW	297	21	*		*		*

NEUROSCIENCE
US	4,886	3,712	31.6		31.6		—
Intl	2,001	2,011	(0.5)		(3.0)		2.5
WW	6,887	5,722	20.3		19.5		0.8

SPRAVATO
US	1,479	1,047	41.3		41.3		—
Intl	197	146	34.8		28.1		6.7
WW	1,676	1,193	40.5		39.7		0.8

CAPLYTA(5)
US	1,029	451	*		*		—
Intl	—	—	—		—		—
WW	1,029	451	*		*		—

INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US	2,235	2,021	10.6		10.6		—
Intl	816	804	1.5		(0.8)		2.3
WW	3,051	2,824	8.0		7.4		0.6

CONCERTA / methylphenidate
US	40	76	(47.3)		(47.3)		—
Intl	386	376	2.4		1.1		1.3
WW	425	452	(5.9)		(7.0)		1.1

See footnotes at end of schedule


	NINE MONTHS
				% Change
	2026		2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)

OTHER NEUROSCIENCE
US	$	104	119	(12.6)	%	(12.6)	%	—	%
Intl	602		684	(12.0)		(14.5)		2.5
WW	706		803	(12.1)		(14.2)		2.1

PULMONARY HYPERTENSION (PH)
US	2,233		2,358	(5.3)		(5.3)		—
Intl	942		895	5.2		2.9		2.3
WW	3,175		3,253	(2.4)		(3.0)		0.6

UPTRAVI
US	1,154		1,139	1.3		1.3		—
Intl	306		272	12.7		7.9		4.8
WW	1,460		1,411	3.5		2.6		0.9

OPSUMIT / OPSYNVI
US	1,042		1,175	(11.3)		(11.3)		—
Intl	538		507	6.0		4.4		1.6
WW	1,580		1,682	(6.1)		(6.6)		0.5

OTHER PULMONARY HYPERTENSION
US	37		44	(15.5)		(15.5)		—
Intl	98		116	(15.6)		(15.3)		(0.3)
WW	135		160	(15.6)		(15.4)		(0.2)

INFECTIOUS DISEASES (ID)
US	959		961	(0.2)		(0.2)		—
Intl	1,506		1,472	2.3		(1.7)		4.0
WW	2,465		2,434	1.3		(1.1)		2.4

EDURANT / rilpivirine
US	15		21	(30.1)		(30.1)		—
Intl	1,131		1,082	4.5		0.6		3.9
WW	1,145		1,103	3.8		0.0		3.8

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US	937		932	0.6		0.6		—
Intl	259		264	(1.9)		(6.2)		4.3
WW	1,196		1,196	0.0		(0.9)		0.9

OTHER INFECTIOUS DISEASES
US	7		8	(11.4)		(11.4)		—
Intl	116		126	(8.0)		(11.7)		3.7
WW	124		135	(8.2)		(11.7)		3.5

See footnotes at end of schedule


	NINE MONTHS
				% Change
	2026		2025	Reported		Operational(1)		Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)

CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US	$	2,235	2,381	(6.1)	%	(6.1)	%	—	%
Intl	378		461	(17.9)		(20.9)		3.0
WW	2,614		2,842	(8.0)		(8.5)		0.5

XARELTO
US	1,959		1,946	0.7		0.7		—
Intl	—		—	—		—		—
WW	1,959		1,946	0.7		0.7		—

OTHER
US	276		435	(36.5)		(36.5)		—
Intl	378		461	(17.9)		(20.9)		3.0
WW	655		896	(26.9)		(28.5)		1.6

TOTAL PH, ID, CVM
US	5,428		5,700	(4.8)		(4.8)		—
Intl	2,826		2,828	(0.1)		(3.4)		3.3
WW	8,254		8,529	(3.2)		(4.3)		1.1

TOTAL INNOVATIVE MEDICINE
US	29,297		26,655	9.9		9.9		—
Intl	19,270		17,983	7.2		3.6		3.6
WW	$	48,567	44,638	8.8	%	7.4	%	1.4	%


	NINE MONTHS
				% Change
	2026		2025	Reported		Operational(1)		Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR
US	$	4,222	3,931	7.4	%	7.4	%	—	%
Intl	2,866		2,698	6.2		3.4		2.8
WW	7,088		6,629	6.9		5.8		1.1

ELECTROPHYSIOLOGY
US	2,290		2,145	6.8		6.8		—
Intl	2,219		2,064	7.5		4.3		3.2
WW	4,509		4,209	7.1		5.6		1.5

ABIOMED
US	1,066		1,035	3.0		3.0		—
Intl	275		256	7.2		5.4		1.8
WW	1,340		1,291	3.8		3.5		0.3

SHOCKWAVE
US	771		659	17.0		17.0		—
Intl	194		169	14.8		15.1		(0.3)
WW	965		828	16.6		16.6		0.0

OTHER CARDIOVASCULAR
US	96		93	3.2		3.2		—
Intl	177		209	(15.0)		(17.7)		2.7
WW	273		302	(9.4)		(11.3)		1.9

SURGERY
US	3,210		3,076	4.3		4.3		—
Intl	4,483		4,417	1.5		(1.6)		3.1
WW	7,692		7,493	2.7		0.8		1.9

ADVANCED
US	1,476		1,411	4.7		4.7		—
Intl	1,991		1,991	0.0		(2.9)		2.9
WW	3,467		3,402	1.9		0.2		1.7

GENERAL
US	1,733		1,666	4.0		4.0		—
Intl	2,492		2,426	2.7		(0.6)		3.3
WW	4,225		4,092	3.3		1.3		2.0

(Dollars in Millions)


	NINE MONTHS
			% Change
	2026	2025	Reported		Operational(1)		Currency
MEDTECH SEGMENT(2)(Continued)
VISION
US	$1,740	1,694	2.7	%	2.7	%	—	%
Intl	2,537	2,354	7.8		6.3		1.5
WW	4,277	4,048	5.6		4.8		0.8

CONTACT LENSES / OTHER
US	1,378	1,337	3.1		3.1		—
Intl	1,669	1,565	6.6		5.5		1.1
WW	3,047	2,902	5.0		4.4		0.6

SURGICAL
US	363	358	1.4		1.4		—
Intl	867	789	10.0		8.0		2.0
WW	1,230	1,147	7.3		5.9		1.4
ORTHOPAEDICS
US	4,353	4,200	3.6		3.6		—
Intl	2,794	2,620	6.6		3.5		3.1
WW	7,146	6,820	4.8		3.6		1.2

HIPS
US	831	796	4.4		4.4		—
Intl	465	440	5.7		2.1		3.6
WW	1,296	1,235	4.9		3.6		1.3

KNEES
US	688	673	2.2		2.2		—
Intl	528	482	9.7		7.1		2.6
WW	1,216	1,155	5.3		4.2		1.1

TRAUMA
US	1,623	1,515	7.1		7.1		—
Intl	880	818	7.6		4.4		3.2
WW	2,504	2,333	7.3		6.2		1.1

SPINE, SPORTS & OTHER
US	1,211	1,216	(0.4)		(0.4)		—
Intl	920	881	4.5		1.5		3.0
WW	2,131	2,096	1.7		0.4		1.3

TOTAL MEDTECH
US	13,525	12,902	4.8		4.8		—
Intl	12,679	12,089	4.9		2.2		2.7
WW	$26,204	24,991	4.9	%	3.5	%	1.4	%